LEGN Legend Biotech Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LEGN

Price (delayed)

$34.34

Market cap

$6.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$5.93B

?
Relative Growth: Rel. Growth: 65
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 26

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated ...

Highlights
The revenue has surged by 56% year-on-year and by 11% since the previous quarter
The gross profit has grown by 31% YoY
The quick ratio has plunged by 62% YoY but it has grown by 9% from the previous quarter
The company's net income rose by 16% QoQ but it fell by 15% YoY
The gross margin has contracted by 16% YoY and by 9% from the previous quarter
The equity is down by 4.9% YoY and by 3.4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LEGN

LEGN stock price

How has the Legend Biotech stock price performed over time
Intraday
-4.56%
1 week
21.51%
1 month
29.58%
1 year
13.11%
YTD
57.96%
QTD
89.83%

Financial performance

How have Legend Biotech's revenue and profit performed over time
Revenue
$1.14B
Gross profit
$626.09M
Operating income
-$134.83M
Net income
-$250.27M
Gross margin
55%
Net margin
-22%
The operating margin has soared by 65% YoY and by 11% QoQ
The revenue has surged by 56% year-on-year and by 11% since the previous quarter
LEGN's operating income is up by 45% year-on-year
The gross profit has grown by 31% YoY

Price vs fundamentals

How does LEGN's price correlate with its fundamentals

Growth

What is Legend Biotech's growth rate over time

Valuation

What is Legend Biotech stock price valuation
P/E
N/A
P/B
6.56
P/S
5.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.21
The EPS has increased by 16% since the previous quarter but it has declined by 15% year-on-year
The stock's price to book (P/B) is 40% more than its last 4 quarters average of 4.9 but 31% less than its 5-year quarterly average of 9.9
The equity is down by 4.9% YoY and by 3.4% from the previous quarter
The P/S is 87% less than the 5-year quarterly average of 43.8 but 8% more than the last 4 quarters average of 5.4
The revenue has surged by 56% year-on-year and by 11% since the previous quarter

Efficiency

How efficient is Legend Biotech business performance
The return on sales has increased by 26% since the previous quarter and by 22% year-on-year
The company's return on equity fell by 24% YoY but it rose by 15% QoQ
LEGN's return on assets is down by 16% year-on-year but it is up by 15% since the previous quarter
LEGN's return on invested capital is up by 15% since the previous quarter but it is down by 13% year-on-year

Dividends

What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEGN.

Financial health

How did Legend Biotech financials performed over time
Legend Biotech's total assets is 154% more than its total liabilities
The quick ratio has plunged by 62% YoY but it has grown by 9% from the previous quarter
Legend Biotech's current ratio has shrunk by 59% YoY but it has increased by 9% QoQ
Legend Biotech's debt is 60% lower than its equity
The debt to equity has grown by 11% YoY but it has contracted by 2.4% from the previous quarter
Legend Biotech's debt has increased by 7% YoY but it has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.